
Opinion|Videos|September 25, 2024
Guiding Patients Through Third-Line mCRC Therapy Decisions
Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
When discussing treatment selection in the third-line setting for metastatic colorectal cancer, how do you frame this conversation with patients, balancing efficacy, safety, and overall prognosis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
2
3 New Study Findings to Look Out for at Menopause Society 2025
3
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5